Mirum Pharmaceuticals, Inc.

NasdaqGM:MIRM Stock Report

Market Cap: US$2.2b

Mirum Pharmaceuticals Management

Management criteria checks 3/4

Mirum Pharmaceuticals' CEO is Chris Peetz, appointed in Mar 2019, has a tenure of 6.17 years. total yearly compensation is $6.60M, comprised of 11.1% salary and 88.9% bonuses, including company stock and options. directly owns 0.64% of the company’s shares, worth $13.86M. The average tenure of the management team and the board of directors is 5.1 years and 5.8 years respectively.

Key information

Chris Peetz

Chief executive officer

US$6.6m

Total compensation

CEO salary percentage11.06%
CEO tenure6.2yrs
CEO ownership0.6%
Management average tenure5.1yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

author-image

FDA And Japanese Approvals Will Open New Markets

Strong revenue growth and recent regulatory approvals are set to expand market reach and positively impact future revenues.

Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities

May 04

Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like

Mar 24

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Looks Inexpensive But Perhaps Not Attractive Enough

Mar 21
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Looks Inexpensive But Perhaps Not Attractive Enough

Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3)

Jan 08

Mirum Pharma: Buy At Dips For Volixibat Potential

Dec 25

Investors Aren't Buying Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Revenues

Dec 09
Investors Aren't Buying Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Revenues

Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results

Nov 15
Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results

Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt?

Nov 03
Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt?

Mirum Pharmaceuticals: Intriguing, But Wait For Volixibat Data Makes Me Bearish

Oct 04

Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition

Jul 17

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Fly 46% But Investors Aren't Buying For Growth

Jul 13
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Fly 46% But Investors Aren't Buying For Growth

Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business And Shares Still Trailing The Industry

May 28
Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business And Shares Still Trailing The Industry

Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value

Apr 22

Mirum Pharmaceuticals: Advancing On Several Key Fronts

Mar 05

There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price

Dec 26
There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price

What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You

Jun 10
What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You

Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts

Apr 18
Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts

Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU

Oct 14

Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth

Aug 17

CEO Compensation Analysis

How has Chris Peetz's remuneration changed compared to Mirum Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$77m

Dec 31 2024US$7mUS$730k

-US$88m

Sep 30 2024n/an/a

-US$100m

Jun 30 2024n/an/a

-US$109m

Mar 31 2024n/an/a

-US$159m

Dec 31 2023US$6mUS$660k

-US$163m

Sep 30 2023n/an/a

-US$164m

Jun 30 2023n/an/a

-US$176m

Mar 31 2023n/an/a

-US$129m

Dec 31 2022US$4mUS$624k

-US$136m

Sep 30 2022n/an/a

-US$42m

Jun 30 2022n/an/a

-US$53m

Mar 31 2022n/an/a

-US$70m

Dec 31 2021US$4mUS$600k

-US$84m

Sep 30 2021n/an/a

-US$179m

Jun 30 2021n/an/a

-US$153m

Mar 31 2021n/an/a

-US$132m

Dec 31 2020US$3mUS$512k

-US$103m

Sep 30 2020n/an/a

-US$84m

Jun 30 2020n/an/a

-US$78m

Mar 31 2020n/an/a

-US$68m

Dec 31 2019US$6mUS$458k

-US$53m

Sep 30 2019n/an/a

-US$61m

Dec 31 2018US$385kUS$32k

-US$26m

Compensation vs Market: Chris's total compensation ($USD6.60M) is about average for companies of similar size in the US market ($USD6.25M).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.

CEO

Chris Peetz (45 yo)

6.2yrs
Tenure
US$6,598,551
Compensation

Mr. Christopher Peetz, also known as Chris, was Independent Director of Alpine Immune Sciences, Inc. from April 24, 2018. He joined the Alpine Immune Sciences, Inc. on April 24, 2018. He is CEO & Director...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Peetz
CEO & Director6.2yrsUS$6.60m0.64%
$ 13.9m
Peter Radovich
COO & President5.1yrsUS$3.34m0.020%
$ 425.4k
Eric Bjerkholt
Chief Financial Officer1.7yrsUS$2.01m0.073%
$ 1.6m
Joanne M. Quan
Chief Medical Officer1.3yrsUS$3.59m0.011%
$ 248.5k
Jean-Luc Girardet
Chief Technical Officerno datano datano data
Pamela Vig
Chief Scientific Officer1.3yrsUS$1.51m0%
$ 0
Andrew McKibben
Senior Vice Presidentno datano datano data
Paul Ross
Chief Compliance Officer5.1yrsno datano data
Erin Campany
Chief People Officer6.3yrsno datano data
Lara Longpre
Chief Development Officer6.4yrsUS$1.51m0%
$ 0
Vinita Kumar
Senior Vice President of Quality3.3yrsno datano data
Jolanda Howe
Senior VP & Global Controllerno datano data0.0049%
$ 106.8k
5.1yrs
Average Tenure
54yo
Average Age

Experienced Management: MIRM's management team is seasoned and experienced (5.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christopher Peetz
CEO & Director6.3yrsUS$6.60m0.64%
$ 13.9m
Patrick Heron
Independent Director6.5yrsUS$358.51k0%
$ 0
Laura Brege
Independent Director5.8yrsUS$383.51k0.020%
$ 440.0k
Michael Grey
Independent Non-Executive Chairman of the Board6.2yrsUS$408.51k0.57%
$ 12.3m
Laurent Fischer
Independent Director5.9yrsUS$378.51k0.014%
$ 297.1k
Timothy Walbert
Independent Director2.1yrsUS$363.51k0%
$ 0
Sona Saira Ramasastry
Independent Director2.9yrsUS$368.51kno data
William Fairey
Independent Director3.8yrsUS$368.51k0%
$ 0
Lon Cardon
Independent Director2.5yrsUS$353.51k0%
$ 0
5.8yrs
Average Tenure
58yo
Average Age

Experienced Board: MIRM's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/27 13:18
End of Day Share Price 2025/05/27 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Mirum Pharmaceuticals, Inc. is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Joshua SchimmerCantor Fitzgerald & Co.
David LebowitzCitigroup Inc